Obstetrics & Gynecology Science

Gynecologic Oncology
Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer: Yutaka Yoneoka, Tsukuru Amano, Akimasa Takahashi, Hiroki Nishimura, Mari Deguchi, Hiroyuki Yamanaka, Yuji Tanaka, Shunichiro Tsuji, Takashi Murakami; Obstet Gynecol Sci. 2024;67(6):534-540. Published online September 27, 2024; DOI: https://doi.org/10.5468/ogs.24075; Full text PubReader ePub PDF

Serum lactate dehydrogenase is a possible predictor of platinum resistance in ovarian cancer: Asami Ikeda, Ken Yamaguchi, Hajime Yamakage, Kaoru Abiko, Noriko Satoh-Asahara, Kenji Takakura, Ikuo Konishi; Obstet Gynecol Sci. 2020;63(6):709-718. Published online September 17, 2020; DOI: https://doi.org/10.5468/ogs.20117
Web of Science 10 Crossref 10; Full text PubReader ePub PDF Supplementary Material

Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy: Dhammapoj Jeerakornpassawat, Prapaporn Suprasert; Obstet Gynecol Sci. 2020;63(1):55-63. Published online December 23, 2019; DOI: https://doi.org/10.5468/ogs.2020.63.1.55
Web of Science 13 Crossref 14; Full text PubReader PDF

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer: Wonkyo Shin, Hye-joo Lee, Seong J. Yang, E sun Paik, Hyun-jin Choi, Tae-Joong Kim, Chel Hun Choi, Jeong-Won Lee, Duk-Soo Bae, Byoung-Gie Kim; Obstet Gynecol Sci. 2018;61(3):352-358. Published online May 9, 2018; DOI: https://doi.org/10.5468/ogs.2018.61.3.352
Crossref 4; Full text PubReader PDF

Diabetes mellitus following platinum-based chemotherapy in gynecologic cancer patients.: Ga Hyun Son, Eun Ji Nam, Sang Wun Kim, Jae Hoon Kim, Young Tae Kim, Sunghoon Kim; Korean J Obstet Gynecol. 2008;51(2):167-172. Published online February 1, 2008

The efficacy and toxicity of topotecan in combination with platinum in patients with recurrent epithelial ovarian cancer and primary peritoneal carcinomatosis.: Hang Jo You, Yong Man Kim, Shin Wha Lee, Jung Nam Lee, Dae Yeon Kim, Dae Shik Suh, Jong Hyeok Kim, Young Tak Kim, Joo Hyun Nam, Jung Eun Mok; Korean J Obstet Gynecol. 2008;51(1):31-40. Published online January 1, 2008

Clinical analysis of Paclitaxel and Platinum in Recurrent Carcinoma of the Uterine Cervix.: Seung Wook Jeon, Young Tak Ju, Ji Hyeon Kim, Ok Joo Ahn, Young Moon, Kwang Beom Lee, Jin Woo Shin, Jong Min Lee, Chan Yong Park; Korean J Obstet Gynecol. 2005;48(6):1448-1455. Published online June 1, 2005

Secondary acute myeloid leukemia after platinum based chemotherapy for ovarian cancer.: Ji Young Kwon, Jin Kyung Park, Seung Yeop Baek, Sue Yeon Kim, Ki Sung Ryu, Jong Gu Rha, Gu Taek Han; Korean J Obstet Gynecol. 2005;48(4):1058-1063. Published online April 1, 2005

Clinical Features of Hypersensitivity Reactions to Cisplatin and Carboplatin.: Yeon Jin Park, Eul Ju Moon, Hee Hwahn Chung, Ju Won Roh, Sang Yoon Park, Young Suk Park; Korean J Obstet Gynecol. 2003;46(5):1018-1023. Published online May 1, 2003

Second-line Chemotherapy with Taxol Containing Regimen in Recurrent or Refractory Ovarian Carcinoma after Platinum-Based Chemotherapy.: M H Kim, N H Park, Y B Kim, C M Lee, J W Kim, Y S Song, S B Kang, H P Lee; Korean J Obstet Gynecol. 1998;41(9):2323-2328. Published online January 1, 2001

Search